Zuellig Pharma acquires Cialis® (Tadalafil) and Alimta® (Pemetrexed) from Lilly in select ASEAN markets
ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand.
"This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world's leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia," said John Graham, Group CEO, Zuellig Pharma.
https://www.zuelligpharma.com/ https://sg.linkedin.com/company/zuellig-pharma
Hashtag: #ZuelligPharma #EliLilly #Acquisition #Healthcare #Pharmaceuticals #Oncology #MensHealth
The issuer is solely responsible for the content of this announcement.
Authors: Zuellig Pharma
Read more https://www.media-outreach.com/news/singapore/2024/02/05/276159/